Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosutinib versus imatinib in newly diagnosed chronic phase CML
NL-OMON25517Phase 3Recruiting
- Sponsor
- Avillion Development 1
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bosutinib, imatinib in chronic myelogenous leukemia (CML), sponsored by Avillion Development 1. Started Jun 2014; status: recruiting.
02
Drugs
bosutinibimatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NL-OMON25517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25517.